Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Normal thiopurine methyltransferase phenotype testing in a Crohn disease patient with azathioprine induced myelosuppression.

Internal medicine journal - 1 Feb 2009

Leung M, Piatkov I, Rochester C, Boyages S C, Leong R W L

Abstract excerpt

Severe cytopenias in patients with autoimmune conditions treated with azathioprine are well-recognized. Thiopurine methyltransferase (TPMT) enzymatic activity is subject to individual and ethnic variability. Patients with low TPMT activity (poor metabolizers) are at high risk of developing severe and potentially fatal haematopoietic toxicity. Studies have shown that essentially all TPMT-deficient patients will...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azathioprine
Share to Bone Marrow Cells
Share to Crohn Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to TPMT gene

Share to Genetic Testing

Share to Methyltransferases

Share to Phenotype

Source

Identifiers

PMID: 19356188
DOI: 10.1111/j.1445-5994.2008.01855.x

Genes

TPMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Normal thiopurine methyltransferase phenotype testing in a Crohn disease patient with azathioprine induced myelosuppression.PMID 19356188Read ↗

Limitations of extensive TPMT genotyping in the management of azathioprine-induced myelosuppression in IBD patients.Semantic proximity Read ↗

Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy.Semantic proximity Read ↗

Thiopurine Drugs in the Treatment of Ulcerative Colitis: Identification of a Novel Deleterious Mutation in TPMT.Semantic proximity Read ↗

Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn's disease.Semantic proximity Read ↗

<i>ITPA</i> genotyping test does not improve detection of Crohn’s disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression: Table 1Semantic proximity Read ↗

Risk factors for thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype.Semantic proximity Read ↗

Azathioprine and 6‐mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel diseaseSemantic proximity Read ↗

Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease?Semantic proximity Read ↗

Update on thiopurine pharmacogenetics in inflammatory bowel disease.Semantic proximity Read ↗

Azathioprine-associated acute myeloid leukemia in a patient with Crohn's disease and thiopurine S-methyltransferase deficiency.Semantic proximity Read ↗

Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease.Semantic proximity Read ↗

Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.